Revenue: As of FY2026 Q1, the actual value is USD 106.51 M, beating the estimate of USD 92.1 M.EPS: As of FY2026 Q1, the actual value is USD 0.24.EBIT: As of FY2026 Q1, the actual value is USD 80.02 M.<h4>Total Revenue</h4>Ironwood Pharmaceuticals, Inc. reported total revenue of $106.5 million in the first quarter of 2026, a significant increase from $41.1 million in the first quarter of 2025 . This revenue consisted of $104.2 million from the company’s share of net profits from LINZESS sales in the U.S. and $2.3 million in royalties and other revenue for the first quarter of 2026 . In the first quarter of 2025, total revenue comprised $38.8 million from LINZESS U.S. net profits share and $2.3 million in royalties and other revenue .<h4>Operational Metrics</h4><ul><li>LINZESS U.S. Net Sales: LINZESS U.S. net sales, as reported by AbbVie Inc., were $272.5 million in the first quarter of 2026, a 97% increase compared to $138.5 million in the first quarter of 2025 . This growth was primarily driven by a 5% demand growth and significantly improved net price .</li><li>LINZESS Prescription Demand: Total LINZESS prescription demand was 56.0 million capsules in the first quarter of 2026, a 5% increase year-over-year compared to the first quarter of 2025 .</li><li>LINZESS Commercial Margin: The commercial margin for LINZESS was 76% in the first quarter of 2026, an increase from 52% in the first quarter of 2025 .</li><li>Net Profit for LINZESS U.S. Brand Collaboration: The net profit for the LINZESS U.S. brand collaboration, net of commercial and R&amp;D expenses, was $204.7 million in the first quarter of 2026, representing a 211% increase compared to $65.9 million in the first quarter of 2025 .</li><li>Collaboration Revenue to Ironwood: Ironwood Pharmaceuticals, Inc. recorded $104.2 million in collaboration revenue related to U.S. LINZESS sales in the first quarter of 2026, a 169% increase from $38.8 million in the first quarter of 2025 .</li><li>Total Costs and Expenses: Total costs and expenses were $33.9 million in the first quarter of 2026, a decrease from $70.3 million in the first quarter of 2025 . Research and development (R&amp;D) expenses decreased to $21.9 million in the first quarter of 2026 from $27.4 million in the first quarter of 2025 . Selling, general and administrative (SG&amp;A) expenses also decreased to $12.0 million from $24.3 million over the same period . Restructuring expenses were - $40 thousand in the first quarter of 2026, compared to $18.6 million in the first quarter of 2025 .</li><li>Interest Expense: Interest expense increased to $9.1 million in the first quarter of 2026 from $8.1 million in the first quarter of 2025 .</li><li>Interest and Investment Income: Interest and investment income rose to $1.7 million in the first quarter of 2026 from $0.9 million in the first quarter of 2025 .</li><li>Income Tax Expense: Income tax expense was $24.4 million in the first quarter of 2026, up from $1.1 million in the first quarter of 2025 .</li><li>GAAP Net Income (Loss): GAAP net income was $40.8 million in the first quarter of 2026, compared to a GAAP net loss of - $37.4 million in the first quarter of 2025 .</li><li>Adjusted EBITDA: Adjusted EBITDA was $76.7 million in the first quarter of 2026, a significant improvement from - $4.7 million in the first quarter of 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Cash and Cash Equivalents: Ironwood Pharmaceuticals, Inc. ended the first quarter of 2026 with $220.5 million in cash and cash equivalents, an increase from $215.5 million at the end of 2025 .</li><li>Cash from Operations: The company generated $5.1 million in cash from operations in the first quarter of 2026, down from $20.0 million in the first quarter of 2025 .</li><li>Accounts Receivable: Accounts receivable totaled $105.8 million as of March 31, 2026 .</li><li>Revolving Credit Facility: The outstanding principal balance on the revolving credit facility was $385.0 million as of March 31, 2026 .</li></ul><h4>Outlook / Guidance</h4>Ironwood Pharmaceuticals, Inc. maintains its full-year 2026 financial guidance . The company expects U.S. LINZESS Net Sales to be between $1.125 billion and $1.175 billion, driven by improved net price and low-single digit percentage demand growth . Total revenue is projected to be between $450 million and $475 million, with Adjusted EBITDA expected to be greater than $300 million .

Ironwood Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 106.51 M